Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07469709 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Biological, Genetic, and Constitutional Factors and Non-invasive Monitoring to Assess Personal Cancer Risks

Study acronym: PRO-ACTIVE
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
Fondazione del Piemonte per l'Oncologia
19 trials monitored
See all monitored trials
Breast Cancer
5,418 trials monitored
See 296 trials at risk
Lung Cancer
4,790 trials monitored
See 263 trials at risk
Colorectal Cancer
3,394 trials monitored
See 159 trials at risk
and 3 more diseases
The PRO-ACTIVE study aims to develop a clinical-translational program in the field of cancer prevention in all its phases (primary, secondary, and tertiary) to intervene before the clinical and radiological manifestation of the disease. It starts with risk prediction and leads to early diagnosis of the disease or recurrence in the subclinical phase. The PRO-ACTIVE study includes the following activities: * WP1: Integrated DNA-RNA approach for the identification of hereditary markers of predisposition to tumors * WP2: Global biological and molecular analysis of the host and tumor for the prevention and monitoring of recurrences * WP3: Analysis of the immunological status for the diagnosis of primary prevention and relapses in correlation to genetic and environmental factors * WP4: Study of the tumor microenvironment for recurrence prediction
Trial Details
NCT Number NCT07469709
Lead Sponsor Fondazione del Piemonte per l'Oncologia
Conditions
(from sponsor)		 Breast Cancer, Colo-rectal Cancer, Ovarian Cancer, Melanoma (Skin Cancer), Non-Small Cell Lung Cancer (MeSH Term: Carcinoma, Non-Small-Cell Lung)
Related terms Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Melanoma, Ovarian Neoplasms
Enrollment 850 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov